Evaluation of comparative efficacy of Jyotishmati Capsule versus Sertraline Capsule in the management of Chittodvega (Generalized Anxiety Disorder) – RCT - GAD

Reeya Gamne0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年4月29日

试验速览

暂无简介。

•1.Patients willing to take part in research study and ready to give written informed consent.
•2.Patients will be selected according to DSM-V, ICD-10 criteria for anxiety disorders.
•3.A score of less than 24on HAM-A scale.
•4.Age group of 20 to 50 years of either sex.
•5.Free of psychiatric conditions other than anxiety.

•1.Current primary diagnosis of a comorbid disorder deemed to require treatment prior to GAD, such as major depressive disorder, panic disorder, social phobia, obsessive compulsive disorder, post-traumatic stress disorder, or drug dependency.
•2.Currently undertaking CBT with a psychologist condition.
•3.GAD (Chittodvega) due to drug abuse, a medication and due to general medical state like Hyperthyroidism
•4.Alcoholic, and Self-harm or suicide risk
•5.Diagnosed with psychosis, schizophrenia, or bipolar illness currently or in the past
•6.Treatment with sertraline for two or more weeks within the previous three months
•7.Pregnant and lactating mothers.

发起方

Reeya Gamne